GlassScriptPhysician profile
Paul A Gill
NPI 1447262076
$3,189.93
in general payments reported to CMS, 2019-2025
23 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $377 · 2021: $637 · 2022: $574 · 2023: $332 · 2024: $394 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $529.23 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $427.45 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Aerie Pharmaceuticals, INC. | $309.65 | 2019-2021 | |
| Alcon Vision LLC | $305.22 | 2022-2025 | Rocklatan, Centurion, Clareon |
| Lensar, INC. | $288.50 | 2021 | |
| Allergan, INC. | $239.78 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $176.50 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $169.33 | 2019-2021 | |
| Amgen INC. | $133.45 | 2024 | Tepezza |
| Tearlab Corp | $108.30 | 2020-2024 | Scoutpro Osmolarity System |
| Johnson & Johnson Surgical Vision, INC. | $93.52 | 2020-2023 | Veritas Vision System |
| Dompe US, INC. | $66.36 | 2022-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $60.62 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $55.42 | 2021 | |
| Shire North American Group INC | $47.00 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $40.15 | 2021 | |
| Biotissue Holdings INC. | $37.72 | 2020-2024 | |
| Ocular Therapeutix, INC. | $25.70 | 2023 | Dextenza |
| Rxsight INC | $18.27 | 2022 | |
| Glaukos Corporation | $17.70 | 2023 | |
| Omeros Corporation | $14.63 | 2019 | |
| Horizon Therapeutics Plc | $14.03 | 2019 | |
| Quidel Corporation | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.